• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种与血管生成相关的长非编码 RNA 标志物与肝癌患者的预后相关。

An angiogenesis-related long noncoding RNA signature correlates with prognosis in patients with hepatocellular carcinoma.

机构信息

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.

Central Laboratory, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.

出版信息

Biosci Rep. 2021 Apr 30;41(4). doi: 10.1042/BSR20204442.

DOI:10.1042/BSR20204442
PMID:33764367
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8026853/
Abstract

Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal cancers worldwide. Neovascularization is closely related to the malignancy of tumors. We constructed a signature of angiogenesis-related long noncoding RNA (lncRNA) to predict the prognosis of patients with HCC. The lncRNA expression matrix of 424 HCC patients was downloaded from The Cancer Genome Atlas (TCGA). First, gene set enrichment analysis (GSEA) was used to distinguish the differentially expressed genes of the angiogenesis genes in liver cancer and adjacent tissues. Next, a signature of angiogenesis-related lncRNAs was constructed using univariate and multivariate analyses, and receiver operating characteristic (ROC) curves were used to assess the accuracy. The signature and relevant clinical information were used to construct the nomogram. A 5-lncRNA signature was highly correlated with overall survival (OS) in HCC patients and performed well in evaluations using the C-index, areas under the curve, and calibration curves. In summary, the 5-lncRNA model can serve as an accurate signature to predict the prognosis of patients with liver cancer, but its mechanism of action must be further elucidated by experiments.

摘要

肝细胞癌(HCC)是全球最常见和最致命的癌症之一。血管生成与肿瘤的恶性程度密切相关。我们构建了一个与血管生成相关的长链非编码 RNA(lncRNA)特征,以预测 HCC 患者的预后。从癌症基因组图谱(TCGA)下载了 424 名 HCC 患者的 lncRNA 表达矩阵。首先,使用基因集富集分析(GSEA)来区分肝癌和相邻组织中血管生成基因的差异表达基因。接下来,使用单变量和多变量分析构建了一个与血管生成相关的 lncRNA 特征,并使用接收器操作特征(ROC)曲线来评估准确性。该特征和相关临床信息用于构建列线图。一个 5-lncRNA 特征与 HCC 患者的总生存期(OS)高度相关,并且在使用 C 指数、曲线下面积和校准曲线进行评估时表现良好。总之,该 5-lncRNA 模型可以作为预测肝癌患者预后的准确特征,但必须通过实验进一步阐明其作用机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4366/8026853/5397bd79bcbb/bsr-41-bsr20204442-g8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4366/8026853/336433277931/bsr-41-bsr20204442-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4366/8026853/08d9f2041348/bsr-41-bsr20204442-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4366/8026853/9b566a29b413/bsr-41-bsr20204442-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4366/8026853/daa4d3d482b5/bsr-41-bsr20204442-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4366/8026853/16711a3f1793/bsr-41-bsr20204442-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4366/8026853/3975b1b784e8/bsr-41-bsr20204442-g6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4366/8026853/875ae431ca93/bsr-41-bsr20204442-g7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4366/8026853/5397bd79bcbb/bsr-41-bsr20204442-g8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4366/8026853/336433277931/bsr-41-bsr20204442-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4366/8026853/08d9f2041348/bsr-41-bsr20204442-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4366/8026853/9b566a29b413/bsr-41-bsr20204442-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4366/8026853/daa4d3d482b5/bsr-41-bsr20204442-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4366/8026853/16711a3f1793/bsr-41-bsr20204442-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4366/8026853/3975b1b784e8/bsr-41-bsr20204442-g6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4366/8026853/875ae431ca93/bsr-41-bsr20204442-g7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4366/8026853/5397bd79bcbb/bsr-41-bsr20204442-g8.jpg

相似文献

1
An angiogenesis-related long noncoding RNA signature correlates with prognosis in patients with hepatocellular carcinoma.一种与血管生成相关的长非编码 RNA 标志物与肝癌患者的预后相关。
Biosci Rep. 2021 Apr 30;41(4). doi: 10.1042/BSR20204442.
2
Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.长链非编码 RNA 标志物预测肝细胞癌无复发生存率。
World J Gastroenterol. 2019 Jan 14;25(2):220-232. doi: 10.3748/wjg.v25.i2.220.
3
A novel seven-lncRNA signature for prognosis prediction in hepatocellular carcinoma.一个新型的七长链非编码 RNA 标志物用于肝细胞癌的预后预测。
J Cell Biochem. 2019 Jan;120(1):213-223. doi: 10.1002/jcb.27321. Epub 2018 Sep 11.
4
15-lncRNA-Based Classifier-Clinicopathologic Nomogram Improves the Prediction of Recurrence in Patients with Hepatocellular Carcinoma.基于 15-lncRNA 的分类器-临床病理列线图改善了肝细胞癌患者复发的预测。
Dis Markers. 2020 Dec 1;2020:9180732. doi: 10.1155/2020/9180732. eCollection 2020.
5
Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.鉴定五个长链非编码 RNA 标志物以改善肝细胞癌患者的预后预测。
World J Gastroenterol. 2018 Aug 14;24(30):3426-3439. doi: 10.3748/wjg.v24.i30.3426.
6
Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.鉴定和描述一个 25-lncRNA 预后标志物用于预测肝细胞癌早期复发。
BMC Cancer. 2021 Oct 30;21(1):1165. doi: 10.1186/s12885-021-08827-z.
7
A New Prognostic Strategy Based on four DNA Repair-Associated lncRNAs for Hepatocellular Carcinoma.基于四个 DNA 修复相关 lncRNA 的新型肝癌预后策略。
Comb Chem High Throughput Screen. 2022;25(5):906-918. doi: 10.2174/1386207324666210302091432.
8
Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.鉴定 m6A 甲基转移酶相关的长链非编码 RNA 特征,以预测肝细胞癌患者的免疫治疗和预后。
Biosci Rep. 2021 Jun 25;41(6). doi: 10.1042/BSR20210760.
9
A four-long noncoding RNA signature predicts survival of hepatocellular carcinoma patients.一个四长非编码 RNA 特征可预测肝癌患者的生存情况。
J Clin Lab Anal. 2020 Sep;34(9):e23377. doi: 10.1002/jcla.23377. Epub 2020 May 30.
10
Long non-coding RNA-based signature for predicting prognosis of hepatocellular carcinoma.基于长非编码 RNA 的signature 用于预测肝细胞癌的预后。
Bioengineered. 2021 Dec;12(1):673-681. doi: 10.1080/21655979.2021.1878763.

引用本文的文献

1
Role of angiogenesis-related lncRNAs in tumor microenvironment and prognosis of lung adenocarcinoma.血管生成相关长链非编码RNA在肺腺癌肿瘤微环境及预后中的作用
Genes Dis. 2025 Jun 11;12(6):101700. doi: 10.1016/j.gendis.2025.101700. eCollection 2025 Nov.
2
A Model to Predict Prognosis of Renal Cell Clear Cell Carcinoma Based on 3 Angiogenesis-related Long Non-coding RNAs.一种基于3种血管生成相关长链非编码RNA预测肾透明细胞癌预后的模型。
J Cancer. 2024 Apr 29;15(11):3481-3494. doi: 10.7150/jca.94685. eCollection 2024.
3
Lnc-CLSTN2-1:1 Promotes Osteosarcoma Progression by Disrupting Redox Balance through PI3K/AKT Signaling Pathway.

本文引用的文献

1
An autophagy-related long non-coding RNA prognostic signature accurately predicts survival outcomes in bladder urothelial carcinoma patients.一个自噬相关的长非编码 RNA 预后签名可准确预测膀胱癌患者的生存结局。
Aging (Albany NY). 2020 Aug 29;12(15):15624-15637. doi: 10.18632/aging.103718.
2
Cancer statistics, 2020.癌症统计数据,2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
3
The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma.
Lnc-CLSTN2-1:1通过PI3K/AKT信号通路破坏氧化还原平衡促进骨肉瘤进展。
J Cancer. 2024 Jan 12;15(5):1287-1298. doi: 10.7150/jca.91579. eCollection 2024.
4
Identifying Treatment Resistance Related Pathways by Analyzing Serum Extracellular Vesicles of Patients With Resistant Versus Regressed Retinoblastoma.通过分析耐药性与消退性视网膜母细胞瘤患者的血清细胞外囊泡来鉴定治疗抵抗相关途径。
Invest Ophthalmol Vis Sci. 2023 Aug 1;64(11):26. doi: 10.1167/iovs.64.11.26.
5
Construction and validation of an angiogenesis-related lncRNA prognostic model in lung adenocarcinoma.肺腺癌中血管生成相关lncRNA预后模型的构建与验证
Front Genet. 2023 Mar 14;14:1083593. doi: 10.3389/fgene.2023.1083593. eCollection 2023.
6
An Angiogenesis-Related lncRNA Signature Is Associated with Prognosis and Tumor Immune Microenvironment in Breast Cancer.一种与血管生成相关的长链非编码RNA特征与乳腺癌的预后及肿瘤免疫微环境相关。
J Pers Med. 2023 Mar 13;13(3):513. doi: 10.3390/jpm13030513.
7
An angiogenesis-related three-long non-coding ribonucleic acid signature predicts the immune landscape and prognosis in hepatocellular carcinoma.一种与血管生成相关的长链非编码核糖核酸特征可预测肝细胞癌的免疫格局和预后。
Heliyon. 2023 Feb 23;9(3):e13989. doi: 10.1016/j.heliyon.2023.e13989. eCollection 2023 Mar.
8
Identification and validation of a novel angiogenesis-related gene signature for predicting prognosis in gastric adenocarcinoma.一种用于预测胃腺癌预后的新型血管生成相关基因特征的鉴定与验证
Front Oncol. 2023 Jan 16;12:965102. doi: 10.3389/fonc.2022.965102. eCollection 2022.
9
The Pyroptosis-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Immunotherapeutic Efficiency in Hepatocellular Carcinoma.焦亡相关长链非编码RNA特征预测肝细胞癌预后并指示免疫治疗疗效
Front Cell Dev Biol. 2022 May 26;10:779269. doi: 10.3389/fcell.2022.779269. eCollection 2022.
10
LncRNAs and the Angiogenic Switch in Cancer: Clinical Significance and Therapeutic Opportunities.长链非编码 RNA 与癌症中的血管生成开关:临床意义和治疗机会。
Genes (Basel). 2022 Jan 15;13(1):152. doi: 10.3390/genes13010152.
微小 RNA 和长链非编码 RNA 在肝癌耐药中的新兴作用。
Mol Cancer. 2019 Oct 25;18(1):147. doi: 10.1186/s12943-019-1086-z.
4
Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance.长非编码 RNA 和外泌体 lncRNA:在乳腺癌转移和耐药中的分类和机制。
Oncogene. 2020 Jan;39(5):953-974. doi: 10.1038/s41388-019-1040-y. Epub 2019 Oct 10.
5
CPAP promotes angiogenesis and metastasis by enhancing STAT3 activity.持续气道正压通气(CPAP)通过增强 STAT3 活性促进血管生成和转移。
Cell Death Differ. 2020 Apr;27(4):1259-1273. doi: 10.1038/s41418-019-0413-7. Epub 2019 Sep 11.
6
A global view of hepatocellular carcinoma: trends, risk, prevention and management.全球视角下的肝细胞癌:趋势、风险、预防与管理。
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604. doi: 10.1038/s41575-019-0186-y. Epub 2019 Aug 22.
7
An autophagy-related long non-coding RNA signature for glioma.一个与自噬相关的长非编码 RNA 标志物用于脑胶质瘤。
FEBS Open Bio. 2019 Mar 5;9(4):653-667. doi: 10.1002/2211-5463.12601. eCollection 2019 Apr.
8
The Intersection between Tumor Angiogenesis and Immune Suppression.肿瘤血管生成与免疫抑制的交集。
Clin Cancer Res. 2019 Sep 15;25(18):5449-5457. doi: 10.1158/1078-0432.CCR-18-1543. Epub 2019 Apr 3.
9
Correction to: “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".对《肝细胞癌:ESMO诊断、治疗及随访临床实践指南》的勘误
Ann Oncol. 2019 May 1;30(5):871-873. doi: 10.1093/annonc/mdy510.
10
The Role of Angiogenesis in Hepatocellular Carcinoma.血管生成在肝细胞癌中的作用。
Clin Cancer Res. 2019 Feb 1;25(3):912-920. doi: 10.1158/1078-0432.CCR-18-1254. Epub 2018 Oct 1.